抗EGFR增强的新辅助免疫疗法与新辅助免疫化学疗法用于局部发达的口腔状细胞癌
Peng Li1, Qiufeng Jin1, Mingwei Su1
1Department of Head Neck and Thyroid, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
Frontiers in immunology
|December 8, 2025
概括
新辅助免疫化学疗法 (NAIC) 显著改善了口腔状细胞癌 (OSCC) 患者的病理完整反应和生存率. 这种方法在局部先进的OSCC中提供了优异的结果,与其他新辅助治疗相比.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 头部和部癌症 头部和部癌症
背景情况:
- 免疫检查点抑制剂具有先进的转移性口腔状细胞癌 (OSCC) 治疗.
- 在OSCC中新辅助免疫疗法的有效性需要进一步研究.
研究的目的:
- 为了比较新辅助免疫化学疗法 (NAIC),新辅助免疫疗法加 cetuximab (NAI-CTX),和新辅助化学疗法 (NAC) 在局部先进的OSCC.
- 评估这些新辅助剂策略的有效性和安全性.
主要方法:
- 对475名患有III期-IVAOSCC.的患者进行了回顾性队列研究.
- 对NAIC,NAI-CTX和NAC组进行比较.
- 主要终点:病理完整反应 (pCR);二次终点:无事件生存率 (EFS),总生存率 (OS),主要病理反应 (mPR),毒性.
主要成果:
- 在NAI-CTX (13.0%) 和NAC (7.3%) 相比,NAIC显示出更高的pCR率 (30.2%).
- 在NAIC中,三年EFS (73.6%) 和OS (78.1%) 的比率显著提高.
- 虽然NAIC的甲状腺功能低下症发病率较高,但NAI-CTX显示了更多与塞图西马布相关的毒性;没有与治疗相关的死亡.
结论:
- NAIC是一种非常有前途的新辅助策略,用于本地先进的OSCC.
- 与NAI-CTX和NAC相比,NAIC提供了优越的病理反应和生存益处.
- 新辅助疗法的疗效与PD-L1表达水平相关.
相关概念视频
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K


